Evaluation of different ways of presenting LipL32 to the immune system with the aim of developing a recombinant vaccine against leptospirosis.

Centro de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Brazil.
Canadian Journal of Microbiology (Impact Factor: 1.2). 05/2007; 53(4):472-9. DOI: 10.1139/w06-138
Source: PubMed

ABSTRACT Leptospirosis, caused by bacteria of the genus Leptospira, is a direct zoonosis with wide geographical distribution. The implications in terms of public health and the economical losses caused by leptospirosis justify the use of a vaccine against Leptospira in human or animal populations at risk. In this study, we used the external membrane protein LipL32 as a model antigen, as it is highly immunogenic. The LipL32 coding sequence was cloned into several expression vectors: (i) pTarget, to create a DNA vaccine; (ii) pUS973, pUS974, and pUS977 for expression in BCG (rBCG); and (iii) pAE, to express the recombinant protein in Escherichia coli, for a subunit vaccine. Mice were immunized with the various constructs, and the immune response was evaluated. The highest humoral immune response was elicited by the subunit vaccine (rLipL32). However, with rBCG, the titer was still rising at the end of the experiment. The serum of vaccinated animals was able to recognize LipL32 on the membrane of the Leptospira, detected by indirect immunofluorescence. A monoclonal antibody anti-LipL32 was shown to inhibit the growth of Leptospira in vitro, indicating potential protection induced by the LipL32 antigen.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Over 230 serovars of Leptospira interrogans have been identified; however few have been completely characterised. The aim of this study was to characterise the proteome of serovar Canicola and to compare this against the serovars of Copenhageni and Pomona. 2D-LC/MS analysis identified 1653 Leptospira proteins in serovar Canicola; 60 of these proteins were common to Copenhageni and Pomona, 16 of which are known to be immunogenic. This study provides the first reported proteome for serovar Canicola and suggests that proteomic comparison of different serovars could be used as a tool for identification of novel target molecules for vaccine development.
    International journal of proteomics. 01/2014; 2014:572901.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Leptospirosis, a worldwide zoonosis, lacks an effective, safe, and cross-protective vaccine. LipL32, the most abundant, immunogenic, and conserved surface lipoprotein present in all pathogenic species of Leptospira, is a promising antigen candidate for a recombinant vaccine. However, several studies have reported a lack of protection when this protein is used as a subunit vaccine. In an attempt to enhance the immune response, we used LipL32 coupled to or coadministered with the B subunit of the Escherichia coli heat-labile enterotoxin (LTB) in a hamster model of leptospirosis. After homologous challenge with 5× the 50% lethal dose (LD(50)) of Leptospira interrogans, animals vaccinated with LipL32 coadministered with LTB and LTB::LipL32 had significantly higher survival rates (P < 0.05) than animals from the control group. This is the first report of a protective immune response afforded by a subunit vaccine using LipL32 and represents an important contribution toward the development of improved leptospirosis vaccines.
    Clinical and vaccine Immunology: CVI 02/2012; 19(5):740-5. · 2.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Leptospirosis is considered to be a re-emerging disease that has impacts on public health both globally and in and Thailand. The leptospires outbreak in Thailand during 1999 was largely due to the etiologic agent Leptospira borgpetersenii serogroup Sejroe. This had a related immunity profile in cows from Thailand, which serovars Tarassovi and Sejroe were prevalent. Development of a vaccine protecting against leptospiral infection in livestock has been considered. One family of proteins being targeted as candidates for vaccine development are leucine-rich repeats (LRRs), which have diverse functions such as bacterial host-pathogen interactions, membrane anchoring, invasion and stimulating host defense mechanisms. Identifying leptospiral LRR proteins containing immunogenic epitopes is important for Leptospirosis vaccine development. In this study, we searched LRR genes from Leptospira borgpetersenii serovar Hardjo-bovis strain L550 and LB179 genomic databases in an attempt to find appropriate LRR proteins for vaccine candidates covering the common genospecies detected in Thailand. The in silico analysis, LRR protein secondary and tertiary structures by 3-D modeling, and T cell epitope prediction & analysis were performed. In conclusion, we have found seven pairs of conserved LRR genes in Leptospira borpetersenii serovars Hardjo-bovis strains JB197 and L550. Only the LBJ_2271 gene was predicted to be LRR motif subfamily membrane protein with an N-terminal signal sequence, 2 transmembrane domains and an N-glycosylated site. The LRR consensus sequence LXXLXLXXNXL was classified in a typical LRR subfamily. The LBJ_2271 gene sequence has highly homology to genes in other pathogenic Leptospira interrogans serovars; LA_1324, LIC_12401, JX26069, JX26070, JX26071 and JX06072. The LBJ_2271 protein was predicted to containin 14 T cell epitopes, 8 of which are predicted T cell epitopes for Major-Histo-Compatability (MHC) alleles HLA-A∗0101, A∗0202, A∗0203, A∗1101, A∗3101, A∗ 6802, and HLA-DRB∗0401 and DRB∗0701, with IC(50) values of 0.90 to 32.28 nM, residing outside of the transmembrane domains. At least 5 promising predicted T cell epitopes for alleles HLA-A0202, -A0203, -A1101, -DRB0401 and -DRB0701 had their IC(50) lower - equal to IC(50) values for the same allele epitopes of known antigenic proteins LigA, LipL32, OMPL1 and LipL36. This study has successfully identified LBJ_2271 as a protein candidate for further study of antigenic immune stimulation for vaccine development.
    Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases 11/2012; · 3.22 Impact Factor


Available from
May 29, 2014